Article

Daratumumab-Based Regimen May Be Superior for First-Line Multiple Myeloma Treatment

In the absence of a direct head-to-head clinical trial, study may help inform treatment selections for stem cell transplant-ineligible patients.

According to results from the PEGASUS study, patients with newly diagnosed multiple myeloma who were treated with a combination regimen including daratumumab (Darzalex, Janssen) showed a longer estimated progression-free survival (PFS) and significantly reduced risk of progression or death.

Daratumumab was approved in combination with lenalidomide-dexamethasone in June 2019 for the treatment of patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant. According to the study authors, the bortezomib-lenalidomide-dexamethasone combination (VRd) has become a preferred regimen for patients with sufficient fitness for triplet therapy.

The PEGASUS study indirectly compared PFS among patients who participated in the phase 3 MAIA clinical trial, which investigated daratumumab plus lenalidomide and dexamethasone in patients who received commonly prescribed bortezomib-containing regimens. In the absence of a direct head-to-head clinical trial, these results may help inform treatment selections for transplant-ineligible patients, according to a press release.

“As we noted in the publication, the PEGASUS study, which indirectly compared patient data from a clinical trial to data from an electronic health database, may potentially help inform decisions for this patient population in multiple myeloma,” said co-author Saad Usmani, MD, MBA, FACP, in a press release.

Investigators used data from the Flatiron Health electronic health record-derived de-identified database to indirectly compare MAIA dexamethasone data with 2 other standard-of-care regimens: VRd and bortezomib, and dexamethasone alone (Vd). According to a press release, the regimen including daratumumab was associated with a 32% lower risk of disease progression or death compared with VRd and a 52% reduction compared with Vd.

These PEGASUS findings build on the MAIA study, which found a 44% reduction in the risk of disease progression or death with daratumumab compared with lenalidomide and dexamethasone alone over a mean follow-up of 28 months.

“With the availability of more data from real-world clinical practice and analytical tools, we were able to compare treatment regimens and assess patient outcomes to gain further insight into the treatment landscape in transplant-ineligible newly diagnosed multiple myeloma, including the use of Darzalex as an important treatment option for this patient population,” concluded Beth Barber, PhD, in a press release.

REFERENCE

Real-world evidence study finds better patient outcomes with Janssen’s daratumumab than bortezomib in multiple myeloma [email]. Received October 12, 2020. Accessed October 12, 2020.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © nimito - stock.adobe.com
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com